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Abstract
Xenotransplantation has the potential to alleviate the organ shortage that prevents many patients 
with end-stage renal disease from enjoying the benefits of kidney transplantation. Despite 
significant advances in other models, pig-to-primate kidney xenotransplantation has met limited 
success. Preformed anti-pig antibodies are an important component of the xenogeneic immune 
response. To address this, we screened a cohort of 34 rhesus macaques for anti-pig antibody levels. 
We then selected animals with both low and high titers of anti-pig antibodies to proceed with 
kidney transplant from galactose-α1,3-galactose knockout/CD55 transgenic pig donors. All 
animals received T-cell depletion followed by maintenance therapy with costimulation blockade 
(either anti-CD154 mAb or belatacept), mycophenolate mofetil, and steroid. The animal with the 
high titer of anti-pig antibody rejected the kidney xenograft within the first week. Low-titer 
animals treated with anti-CD154 antibody, but not belatacept exhibited prolonged kidney 
xenograft survival (>133 and >126 vs. 14 and 21 days, respectively). Long-term surviving animals 
treated with the anti-CD154-based regimen continue to have normal kidney function and preserved 
renal architecture without evidence of rejection on biopsies sampled at day 100. This description 
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of the longest reported survival of pig-to-non-human primate kidney xenotransplantation, now 
>125 days, provides promise for further study and potential clinical translation.
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 Introduction
Kidney transplantation is the treatment of choice for most individuals with impending or 
established end-stage renal disease. A major barrier to transplantation is the long-standing 
and ever-increasing disparity between the number of individuals listed for transplantation 
and the number of available organs. Xenotransplantation using pig organs has been proposed 
as a potential solution to the organ supply shortage [1,2]. Early attempts at 
xenotransplantation revealed the formidable immune barrier that exists between species, 
specifically hyperacute rejection resulting from natural preformed antibodies. One of the 
most important xenoantigens identified was galactose-α1,3-galactose (αGal), which is 
expressed by pigs but not Old World primates and humans. The development of pigs 
genetically altered to lack αGal expression or engineered to transgenically express human 
complement- and thrombo-regulatory proteins has significantly improved but not eliminated 
the barrier to successful xenotransplantation [3,4]. Recent reports have detailed prolonged 
survival in a pig-to-baboon heterotopic heart model using antibody therapy targeting CD154 
with one animal surviving longer than 1 yr [5]. Interestingly, progress in pig-to-monkey 
kidney xenotransplantation, where the graft is life sustaining, has been less impressive with 
median survival times of a few weeks and the longest reported survival of a single animal at 
90 days [6]. Recipients frequently develop thrombotic microangiopathy and an 
accompanying consumptive coagulopathy characterized by severe thrombocytopenia [7]. 
Presumably this pathology is mediated by preformed, natural anti-pig antibody binding to 
the renal endothelium with resultant complement and coagulation cascade activation [8–11]. 
Because preformed antibodies are an important contributor to xenograft rejection, we 
screened a cohort of rhesus macaques for anti-pig antibody and selected potential recipients 
with both low and high titers. Here, we present our preliminary findings including the long-
term survival (>125 days) of pig-to-non-human primate (NHP) kidney transplants using 
αGal knockout/CD55 transgenic pigs and an anti-CD154-based immunosuppressive 
protocol.
 Material and methods
 Animals
Four αGal knockout/CD55 transgenic pigs (α-1,3-galactosyltransferase knockout, human 
decay-accelerating factor transgenic), aged 10–14 weeks, were obtained from the National 
Swine Resource and Research Center (University of Missouri-Columbia, Columbia, MO, 
USA) to serve as kidney donors. Five rhesus macaques were selected as renal transplant 
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recipients based on preformed IgG serum antibody levels against porcine αGal knockout 
cells, as described below.
 Pre-transplant serum antibody screening
Blood samples were collected from cloned αGal knockout pigs and separated using Ficoll-
Paque Plus to collect peripheral blood mononuclear cells (PBMCs). Serum samples from 34 
rhesus macaque transplant candidates were incubated with porcine αGal knockout PBMCs 
and then stained with anti-human IgM or anti-human IgG conjugated to Alexa-488 (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA, USA). Results were collected on an 
Accuri C6 flow cytometer with analysis of antibody binding by FlowJo version 8.8.7 
(Treestar Inc., Ashland, OR, USA). Flow cytometry results were reported as molecules of 
equivalent soluble fluorochrome (MESF), and animals were ranked according to IgG and 
IgM preformed antibody titers. Four primates with the lowest preformed IgG titers and one 
macaque with the highest IgG titers were selected for transplantation.
 Pig-to-primate renal transplantation
Galactose-α1,3-galactose knockout/CD55 transgenic pigs underwent unilateral or bilateral 
nephrectomy on the day of transplantation (Division of Animal Resources, Emory 
University, Atlanta, GA, USA). Rhesus macaques then underwent bilateral nephrectomy 
followed by life-sustaining renal transplantation with a donor porcine kidney (Yerkes 
National Primate Research Center, Emory University, Atlanta, GA, USA). Surgeries were 
performed in accordance with Institutional Animal Care and Use Committee regulations. 
Postoperatively, graft function was monitored with daily urine output assessment and weekly 
serum chemistries. Peripheral blood was collected for weekly cell subset analysis using flow 
cytometry. Quantitative cytomegalovirus (CMV) titers were measured weekly using a 
polymerase chain reaction (PCR)-based assay. Ultrasound-guided renal biopsies were 
performed postoperatively at days 14, 35, 70, and 100. Biopsy specimens were submitted for 
hematoxylin and eosin staining. Histologic analysis was performed by a blinded renal 
pathologist. Endpoint criteria for euthanasia were defined as serum creatinine >5 mg/dl or 
blood urea nitrogen > 100 mg/dl on two consecutive measurements.
 Treatment regimen
Monkeys underwent T-cell depletion using anti-CD4 and anti-CD8 mAb plus costimulation 
blockade, either anti-CD154 or belatacept, and daily mycophenolate mofetil (MMF) and 
steroids (Table 1). T-cell depletion began 1–3 days prior to transplantation with a one-time 
dose of anti-CD4 50 mg/kg IV (clone CD4R1; NIH Nonhuman Primate Reagent Resource, 
Boston, MA, USA). Anti-CD8 (clone M-T807R1; NIH Nonhuman Primate Reagent 
Resource) was administered on postoperative day (POD) 0 at 50 mg/kg IV. Anti-CD154 
(5c8; NIH Nonhuman Primate Reagent Resource) or belatacept (McKesson Medical, San 
Francisco, CA, USA) was given at 20 mg/kg IV on days 0, 7, and 14 then biweekly. 
Prophylactic enrofloxacin, fluconazole, and ganciclovir were started on the day of 
transplant. Fluconazole and enrofloxacin were discontinued when flow cytometry 
demonstrated sustained T-cell reconstitution. Ganciclovir was continued until CMV titers 
were negative on two consecutive measurements. Weekly subcutaneous Epogen injections 
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were started for hemoglobin less than 9.5 g/dl and discontinued when hemoglobin reached 
12 g/dl.
 Flow cytometry
Peripheral blood was collected weekly to assess the effect of T-cell-depleting antibodies. 
Fluorescent mAbs against primate CD3 (SP34-2), CD4 (L200), and CD16 (3G8) were 
obtained from BD Biosciences (San Jose, CA, USA). Anti-human CD8 (DK25) was 
purchased from EMD Millipore (Billerica, MA, USA). Anti-primate CD19 (CB19) was 
acquired from Abcam (Cambridge, MA, USA). Samples were collected on a BD 
Biosciences LSR II flow cytometer and analyzed using FlowJo software, version 10.0.7 
(Treestar Inc.).
 Cytomegalovirus assays
Porcine PBMCs, splenocytes, and lymphocytes derived from mesenteric lymph node were 
tested for porcine CMV by Zoologix, Inc. (Chatsworth, CA, USA) using real-time PCR. 
Primate PBMCs, renal biopsy samples, splenocytes, and/or lymph node-derived 
lymphocytes were also tested for porcine CMV. Fresh peripheral blood samples from 
monkeys were tested weekly for quantitative CMV viral loads using a primate-specific 
assay. Porcine PBMCs from two pigs were tested using the primate CMV assay to assess for 
cross-reactivity between assays.
 Statistical analyses
Post-transplant survival times were plotted and compared using Kaplan–Meier survival 
curves and log-rank tests with P-values <0.05 considered significant. All analyses were 
performed using Graph-Pad Prism, version 6.0 (La Jolla, CA, USA).
 Results
 Antibody titers and T-cell depletion
Serum samples from a cohort of 34 juvenile rhesus macaques of similar size and age were 
tested for anti-pig antibodies using a flow cytometric anti-pig cross-match assay (Figure S1). 
Based on these results, five recipient animals were selected to proceed with αGal knockout/
CD55 transgenic pig-to-non-human primate kidney transplantation. Preformed anti-pig IgG 
antibody titers in the low-titer group of primates ranged from 1286 to 1599 MESF. IgM 
titers for the same group were 8410 to 20 517 MESF. IgG and IgM titers for the sole high-
titer animal were 23 478 and 37 016 MESF, respectively (Fig. 1). All animals received 
similar immunosuppression consisting of the following: (i) T-cell depletion using a single 
dose of anti-CD4 and anti-CD8 given just prior to transplant; (ii) costimulation blockade 
(either anti-CD154 mAb or belatacept); and (iii) daily MMF and steroid. Flow cytometric 
analysis of peripheral blood subsets demonstrated effective CD8+ T-cell depletion in all 
animals with repopulation occurring around 60 days after transplant (Fig. 2A). Post-
treatment CD4+ T-cell counts were more variable, in that two of five animals displayed 
complete CD4+ T-cell depletion while the remaining three animals retained detectable CD4+ 
cells to varying degrees (Fig. 2B). In the two animals with effective CD4+ depletion, there 
was slow reconstitution of this compartment over time.
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 Costimulation blockade with anti-CD154, but not belatacept, promotes long-term survival 
in monkeys with low anti-pig antibody titers
Non-human primate recipients were selected based on their pre-transplant anti-pig antibody 
titers. Given the proven benefits of anti-CD154 therapy in both cellular and solid organ 
experimental xenograft models, we selected an initial immunosuppression regimen 
consisting of induction with T-cell-depleting mAb and maintenance immunosuppression 
with anti-CD154, MMF, and steroid. Both low and high anti-pig antibody titer animals 
underwent kidney xenotransplantation. Despite initial early graft function, the animal with a 
high titer of anti-pig antibody quickly rejected the xenograft within the first-week post-
transplant (Fig. 3A, Table 1). Clinical rejection was accompanied by severe anemia 
(hemoglobin 4.7 g/dl) and thrombocytopenia (platelets 4 × 103/μl). Pathology revealed 
severe interstitial hemorrhage and edema with minimal cellular infiltrate as well as other 
histologic findings consistent with acute antibody-mediated rejection, including C4d and 
IgG deposition (Fig. 4A–H). In contrast, animals with low levels of pre-transplant anti-pig 
IgG who were treated with an anti-CD154 containing immunosuppressive regimen continue 
to have preserved renal function, now >125 days post-transplant (Fig. 3A, Table 1). Protocol 
kidney xenograft biopsies from day 100 revealed preserved renal architecture and minimal 
cellular infiltrate without evidence of rejection (Fig. 4K).
Although several costimulation blockade reagents, including antibodies against CD40 and 
CD154, are currently at various stages of clinical development, belatacept, a mutated form 
of CTLA-4-Ig that blocks binding of CD80/86 to CD28 on T cells, remains the only reagent 
that is presently approved for use in transplant recipients. Accordingly, we tested whether 
treatment with belatacept instead of anti-CD154 would prolong kidney xenograft survival. 
Despite low titers of anti-pig antibodies prior to transplant, recipients treated with the 
belatacept-based regimen rejected their xenografts at 2- and 3-weeks post-transplant (Fig. 
3A, Table 1). Histologic analysis revealed a mixture of features consistent with acute cellular 
and antibody-mediated rejection as well as evidence of thrombotic microangiopathy (Fig. 
4I,J).
 Electrolyte and hematologic parameters
Previous reports have confirmed the ability of the pig kidney to support normal renal 
function in a non-human primate recipient. However, some alterations in electrolytes and 
hematologic parameters in the post-transplant period were detected [12,13]. We encountered 
similar findings in our cohort of transplanted animals. In animals with functioning grafts, 
creatinine and potassium levels remained within normal limits (Fig. 3A,B). Phosphorus 
levels slowly declined over time, while serum calcium levels correspondingly increased (Fig. 
3C,D). PTH values were assessed in the long-term survivors and were appropriately 
suppressed (data not shown).
Previous studies have reported significant anemia in macaques following kidney 
xenotransplantation [13]. This was attributed to decreased activity of porcine erythropoietin 
in non-human primate recipients. We chose to preemptively treat animals with recombinant 
human erythropoietin (rhEpo) when hemoglobin levels dropped below 9.5 g/dl. Long-term 
survivors, supported with exogenous rhEpo, maintained stable hematologic values post-
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transplant, while recipients that experienced early rejection developed significant anemia 
despite rhEpo therapy (Fig. 5A). Severe thrombocytopenia has been observed frequently 
following pig-to-non-human primate kidney xenotransplantation. Animals that experienced 
early rejection had a significant drop in their platelet counts post-transplant including one 
animal with severe thrombocytopenia (platelets 4 × 103/μl). In contrast, animals with 
preserved xenograft function continue to have stable platelet counts over time (Fig. 5B).
 Cytomegalovirus viral reactivation
Recent reports have suggested that CMV, particularly the infection status of the donor pig, 
may be an important factor in determining post-xenotransplant outcomes [14,15]. All of the 
αGal knock out/CD55 transgenic pig donors used in this study tested positive for porcine 
CMV (pCMV, data not shown). As part of the post-transplant treatment regimen, all animals 
were placed on prophylactic ganciclovir therapy. Peripheral blood samples from all 
recipients were tested weekly for rhesus CMV (rhCMV) using a PCR-based assay 
previously described. Three of the five animals developed significant rhCMV viremia (>10 
000 copies/ml) requiring treatment (Fig. 6). This was most profound in macaques with 
significant T-cell depletion. As expected, rhCMV viral loads improved with T-cell 
reconstitution. Given the significant degree of viremia, tissue samples from xenograft 
recipients were then tested for detection of pCMV. A single renal xenograft biopsy specimen 
tested positive for pCMV. All other tissues from transplant recipients were negative for the 
presence of pCMV DNA (Table 2). Despite established pCMV infection in the donor pigs, 
we were able to achieve long-term xenograft survival using an anti-CD154-based 
immunosuppression regimen.
 Discussion
Despite the remarkable progress in the field of transplantation over the last few decades, the 
shortage of available organs continues to be a major limitation. The use of organs from other 
species has been a theoretical solution but has been fraught with challenges. Significant 
progress has been made in the field of xenotransplantation particularly with the advent of 
genetically engineered pigs. The elimination of αGal represented a major step forward in 
preventing hyperacute rejection. In addition, the ability to express human complement and 
thromboregulatory proteins in pigs was a critical step to improve the known dysregulation of 
both the complement and coagulation cascades that occurs following xenotransplantation. 
Notwithstanding these advances, there has been limited success in kidney 
xenotransplantation with average survival times of a few weeks and the longest recorded 
non-human primate recipient of a pig kidney surviving to 90 days [6,16,17]. Here, we 
describe the longest ongoing survival time (>125 days) reported to date in a life-sustaining, 
pig-to-non-human primate renal xenograft model using an anti-CD154-based 
immunosuppression regimen.
While anti-Gal antibodies represent an important component of the humoral response to 
xenogeneic organs, it is now clear that there are additional pig antigens that are recognized 
by natural antibodies found in humans and primates and that these antibodies contribute to 
xenograft rejection [18]. These non-Gal antibodies are a major barrier to successful kidney 
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xenotransplantation. Similar to humans, the titers of natural anti-non-Gal antibodies in NHPs 
vary significantly between individuals. We tested a large cohort of animals for non-Gal 
antibody levels and then selected animals with low and high titers to proceed with 
xenotransplant. As expected the level of pre-transplant, non-Gal anti-pig antibody played an 
important role in determining post-transplant outcomes in our study. There are numerous pig 
antigens, likely glycoproteins or glycolipids, that serve as targets for preformed antibody 
despite the absence of αGal. These non-Gal antibodies have been detected in human and 
non-human primate serum and at least some of them can mediate complement-dependent 
lysis and antibody-dependent cellular cytotoxicity to pig cells [19,20]. Previous reports have 
identified two important glycosyltransferases, cytidine monophospho-N-acetylneuraminic 
acid hydroxylase (CMAH) and β-1,4 N-acetylgalactosaminyl transferase (β4GalNT2), that 
contribute to the production of important xenoantigens in humans and non-human primates 
[21–24]. Selective deletion of these enzymes in combination with the enzyme responsible 
for αGal production, 1,3-galactosyl transferase, has the potential to lower the pre-transplant 
anti-pig antibody titers to a point where we might consistently achieve long-term kidney 
xenograft function in most if not all recipients when treated with an effective 
immunosuppression regimen [25–27].
In our study, high titers of anti-pig antibody pre-transplant resulted in an accelerated form of 
acute humoral xenograft rejection while low titers had variable results depending on the 
immunosuppression regimen. The two immunosuppression regimens only differed by the 
reagent used to block T-cell costimulation, either belatacept or anti-CD154. We selected 
belatacept as it is the only costimulation blockade reagent currently approved for use in 
transplantation. We have previously reported its efficacy in several non-human primate 
models of allotransplantation [28,29]. Despite having low titers of anti-pig antibody pre-
transplant, xenograft recipients receiving belatacept underwent rejection early post-
transplant (2 and 3 weeks). Histologically, there were features of both antibody and cellular 
rejection. Despite the protective effects of belatacept on renal function and cardiovascular 
risk, there is a significantly higher rate of rejection in belatacept-treated patients [30]. There 
may be several reasons why belatacept failed to control the xenogeneic response. Belatacept 
binds to both CD80 and CD86 and blocks their interactions with the T-cell costimulatory 
molecule CD28. This interaction also limits binding of CTLA-4 and the resultant 
coinhibitory signals [31]. This imbalance of not only costimulatory but also co-inhibitory 
signals may ultimately impact T-cell differentiation and function, particularly in certain T-
cell subsets such as regulatory T cells that may be dependent on those coinhibitory signals. 
In addition for reasons that are unclear, the level of CD4+ T-cell depletion in the animals 
treated with belatacept was less complete than those who were treated with anti-CD154.
Another potential reason for the lack of efficacy may be related to the development of 
belatacept. Point mutations were introduced to increase the binding activity of the parent 
molecule, CTLA-4-Ig, which resulted in increased binding affinity to human CD80 and 
CD86. Interestingly, these changes also eliminated the ability of belatacept to bind to the 
murine versions of CD80 and CD86. Similarly, there is also some question as to how well 
belatacept binds to porcine CD80 and CD86. This may provide a plausible explanation for 
its decreased efficacy [32]. Newer reagents have recently been developed to specifically 
target CD28 and potentially eliminate both of these concerns; permitting coinhibitory signals 
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through CTLA-4 and targeting CD28 directly which is expressed on the recipient T cells 
(human or non-human primate). We and others have shown promising results with these 
reagents in allotransplantation [33–35].
In contrast to the belatacept-treated cohort, animals with low titers of anti-pig antibody 
which received the anti-CD154 containing regimen continue to enjoy rejection-free survival 
now greater than 4 months post-transplant. Blockade of the CD40-CD154 pathway seems to 
be a critical component of most immunosuppression regimens that result in long-term 
survival of solid organ or cellular xenografts [36–38]. Previous attempts to introduce anti-
CD154 therapies for clinical use were met with several challenges including an increased 
incidence of thromboembolic events. We and others have focused our efforts on the 
development of safer alternatives including antibodies to CD40 and novel domain antibodies 
targeting CD154 which are presumably devoid of the unwanted side effects seen with 
previous anti-CD154 therapies [39–41]. Some of these reagents are moving forward in 
clinical trials of autoimmunity and transplantation. The availability of such reagents in 
combination with novel pigs, genetically engineered to lower preformed xenoreactive 
antibodies to acceptable levels, could provide a means of advancing xenotransplantation 
from the experimental to a clinical reality.
 Supplementary Material
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 Abbreviations
ACR acute cellular rejection
AMR antibody-mediated rejection
CMV cytomegalovirus
Hgb hemoglobin
mAbs monoclonal antibodies
MESF molecules of equivalent soluble fluorochrome
MMF mycophenolate mofetil
PBMCs peripheral blood mononuclear cells
PCR polymerase chain reaction
POD postoperative day
PTH parathyroid hormone
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Fig. 1. 
Pre-transplant antibody titers against galactose-α1,3-galactose (αGal) knockout pig cells. 
Thirty-four non-transplanted rhesus macaques were screened for IgG and IgM antibody 
titers against porcine αGal knockout peripheral blood mononuclear cells. (A) Four monkeys 
with the lowest IgG titers were selected to receive a porcine αGal knockout/CD55 transgenic 
renal xenograft. One monkey with the highest IgG titer was also selected. (B) IgM levels 
varied across treatment group.
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Fig. 2. 
Flow cytometric analysis of peripheral blood in animals receiving T-cell depletion. 
Peripheral blood immunophenotypic analysis was performed using flow cytometry. Baseline 
total T-cell, CD8+ T-cell, and CD4+ T-cell counts were measured prior to administration of 
T-cell-depleting antibodies. After xenotransplantation, weekly flow cytometry was 
performed to monitor for reconstitution of T-cell populations. Low-titer, anti-CD154 
monkeys are represented by open and filled squares. Low-titer, belatacept monkeys are 
depicted as open and filled circles. High-titer, anti-CD154 monkey is shown as open 
triangles. (A) Successful CD8+ T-cell depletion was achieved in each monkey with full 
reconstitution occurring after POD 60. (B) Variable CD4+ T-cell depletion was observed 
among animals, with slow reconstitution of this population over time.
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Fig. 3. 
Serum creatinine and electrolyte levels after pig-to-primate renal xenotransplantation. Serum 
chemistries were obtained on a weekly basis post-transplant to monitor graft function. 
Shading depicts normal electrolyte ranges for rhesus macaques. Low-titer, anti-CD154 
monkeys are represented by open and filled squares. Low-titer, belatacept monkeys are 
depicted as open and filled circles. High-titer, anti-CD154 monkey is shown as open 
triangles. (A) In monkeys with functioning grafts, creatinine values remained within the 
expected range. (B) Potassium levels remained constant and within normal limits post-
transplant. (C) Phosphorus decreased over time, most notably after postoperative day 60. (D) 
Calcium levels increased after transplant with levels slightly higher than the anticipated 
range for macaques.
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Fig. 4. 
Gross appearance, histology, and immunofluorescence of pig-to-primate renal xenografts. 
Protocol renal biopsies were obtained at postoperative day (POD) 14, 35, 70, and 100. At 
rejection, animals underwent transplant nephrectomy with subsequent histologic analysis. 
(A, B) Animals that rejected early (POD 6–21) demonstrated gross congestion and 
hemorrhage in the xenograft at time of rejection. (C, D) H&E staining of rejected renal 
xenograft in the high-titer monkey demonstrated interstitial hemorrhage and edema. C4d 
staining was positive, consistent with antibody-mediated rejection. (E–H) 
Immunofluorescence in the high-titer monkey showed significant deposition of IgG, but not 
IgM, in the rejected xenograft. Fixed porcine tissue was stained with DAPI (blue) and 
AF647-anti-IgG or AF647-anti-IgM (red). (E) IgG and (F) IgM staining in a control non-
transplanted αGal knockout porcine kidney showed no antibody deposition. (G) Substantial 
IgG binding was seen in the transplanted renal xenograft at the time of rejection. (H) 
Minimal IgM staining was seen in the same rejected xenograft. (I, J) H&E staining of 
rejected xenograft in low-titer, belatacept-treated monkeys showed evidence of antibody-
mediated rejection and acute cellular rejection. Both thrombotic microangiopathy (I) and 
arteritis (J) were seen. (K) H&E staining of protocol renal biopsies in low-titer, anti-CD154-
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treated monkeys demonstrated preserved renal architecture and no evidence of rejection at 
POD 100.
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Fig. 5. 
Hemoglobin and platelet measurements after pig-to-primate renal xenotransplantation. 
Hemoglobin and platelet counts were monitored on a weekly basis. (A) All monkeys started 
exogenous rhEpo when hemoglobin dropped below 9.5 g/dl. Time of rhEpo initiation ranged 
from postoperative day 1–20. Two of three animals with histology-proven rejection 
developed severe anemia at time of rejection. Animals with functioning grafts maintained 
normal hemoglobin values. (B) Platelet counts remained stable over time in animals without 
clinical or histologic evidence of rejection. Two animals with antibody-mediated rejection 
developed significant thrombocytopenia at time of rejection.
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Fig. 6. 
Cytomegalovirus (CMV) titers following T-cell depletion and costimulation blockade. CMV 
titers were measured weekly using polymerase chain reaction. Standard cutoff for initiation 
of antiviral therapy is greater than 10 000 copies/ml. However, given the concern for CMV 
viremia in the setting of T-cell depletion, all monkeys were started on prophylactic 
ganciclovir beginning the day of transplant. Despite this, two monkeys with the greatest T-
cell depletion developed significant CMV viremia. As T-cell counts recovered, CMV titers 
improved.
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Table 1
Treatment and survival times following pig-to-primate renal xenotransplantation. Monkeys were divided into 
three treatment arms: (i) low pre-transplant anti-pig titers and anti-CD154 costimulatory blockade; (ii) low 
titer and belatacept; and (iii) high titer and anti-CD154. Survival ranged from 14 to >133 days in low-titer 
monkeys with 6-day survival in the high-titer monkey. Among the low-titer group, improved survival was 
observed in animals treated with anti-CD154
NHP Pre-transplant, anti-pig Ab titers Therapy Survival (days)
#1 Low titer Anti-CD4, anti-CD8, anti-CD154, MMF/steroids >133
#2 Low titer Anti-CD4, anti-CD8, anti-CD154, MMF/steroids >126
#3 Low titer Anti-CD4, anti-CD8, belatacept, MMF/steroids     14
#4 Low titer Anti-CD4, anti-CD8, belatacept, MMF/steroids     21
#5 High titer Anti-CD4, anti-CD8, anti-CD154, MMF/steroids       6
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Table 2
Non-human primate tissues tested for porcine cytomegalovirus (CMV) using porcine-specific CMV assay. 
Tissue from xenotransplant recipients was tested for porcine CMV given the significant degree of CMV viral 
loads detected in the peripheral blood. Only one transplanted xenograft tested positive for porcine CMV
NHP Tissue(s) Porcine CMV assay
#1 Kidney Neg
#3 Kidney Neg
Lymph node Neg
Spleen Neg
PBMC Neg
#4 Kidney Pos
#5 Kidney Neg
Lymph node Neg
PBMC Neg
PBMC, peripheral blood mononuclear cells.
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